Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 14, 2024
Deals
Lundbeck bolts on Longboard, gains anticonvulsive in $2.6B deal
Danish pharma eyeing growth beyond loss of exclusivity for Rexulti, aiming for broad label in rare epilepsies
BioCentury | Jun 2, 2023
Product Development
Epigenome editing companies showcase progress at ASGCT
Modalis accomplishes gene activation, while Tune achieves gene repression, both in non-human primates
BioCentury | May 26, 2023
Data Byte
CHMP seeks to pull Adakveo’s conditional approval; drug has full FDA approval
EMA agency issues positive opinions on Pylclari and Ztalmy, label expansions for Opdivo and Sogroya
BioCentury | Jan 19, 2023
Politics, Policy & Law
Hopes, Fears for Orphan Drug Act
Passed 40 years ago, it may be time for ODA 2.0
BioCentury | Nov 18, 2022
Regulation
Nov. 17 Quick Takes: FDA approves Provention’s mAb to slow onset of diabetes
Plus: Rezo’s launch, deals by Regeneron-CytomX and Marinus-Tenacia, the end of a GSK-Immatics deal, and Tenaya’s funding
BioCentury | Nov 9, 2022
Regulation
Nov. 8 Quick Takes: FDA request could extend review of BioMarin’s hemophilia therapy
Plus Sanofi’s latest AI deal taps Insilico and updates from Kronos, Marinus and more
BioCentury | Jul 15, 2022
Politics, Policy & Law
July 14 Quick Takes: Illumina, BGI end U.S. legal battle
Plus FDA delays BeiGene’s BLA, Manifold raises $40M and updates from Theravance, Marinus, and more
BioCentury | Mar 1, 2022
Data Byte
At least nine PDUFA dates on deck in March
Four submissions under FDA priority review
BioCentury | Feb 24, 2022
Deals
Amicus deprioritizes gene therapies, ends plan to merge spinout with Perceptive’s SPAC
After years of building gene therapy pipeline, Amicus refines focus to Fabry, Pompe franchises
BioCentury | Sep 29, 2021
Deals
Amicus’ Crowley to lead gene therapy spinout after SPAC deal
Amicus will be largest shareholder in newly launched Caritas, which will advance genetic medicines pipeline
Items per page:
1 - 10 of 24